In Response:
We thank Secemsky et al for their constructive remarks on our study 1 ; and comments that are equally applicable to all observational studies. We fully concur that residual confounding factors may be a potential explanation for our study findings, demonstrating vascular closure devices (VCDs) to be associated with a minor short-term (30-day) mortality impact, a fact that was openly acknowledged throughout the article. We also fully recognize that methods to minimize confounding in registry data should be utilized wherever possible, recognizing that registries by their inherent design can never fully account for residual confounding, no matter how robust the analysis performed. 2 In addition, it should be highlighted that the propensity score correction adopted during our study was extremely comprehensive, with all important recorded confounding factors included. With this backdrop, comments stating that residual confounding to be the most likely explanation for our study findings appear unjustified.
As demonstrated in our study, the overall short-term mortality benefit for VCDs compared with manual pressure after propensity score correction was minor (30-day corrected mortality: manual pressure, 2.0% versus VCD 1.8%; P=0.0037), which most operators are likely to regard as of limited clinical relevance. The fact that this mortality benefit was seen (if real) may be related to the study being population based and was all-comers with no exclusion criteria applied, capturing all femoral-based percutaneous coronary interventions (PCI) conducted in the United Kingdom over a 5-year period (n=271 845). To further understand this potential mortality benefit, we performed prespecified subgroup analyses in patient subsets that were known to be at high risk of bleeding. 3 Notably, we demonstrated that it was precisely these patients-women, presentation with acute coronary syndrome, or recent lysis-that had positive interaction P values, thus suggesting the potential short-term mortality benefit to be much greater. As highlighted in our study, 1 these findings directly contradict the 2010 American Heart Association guidelines, which give a class III recommendation (procedure should not be performed because it is not helpful and may be harmful) when VCDs are used with the intent to reduce vascular complications. It should, however, be emphasized that we were unable to correlate the short-term mortality findings with vascular complications because of systematic under-reporting in the British Cardiovascular Intervention Society database, a fact that we openly acknowledged in the study. Instead, we were reliant on other studies-namely, the CathPCI registry 4 and now that from Wimmer et al 5 -which had accurately collected the vascular complication rates to allow us to gain a mechanistic insight to potentially account for our study findings. Notably, Wimmer et al 5 calculated that 250 patients would need to be treated with VCD to prevent 1 vascular access site complication, a number that may well be reduced and/or the clinical impact of the bleed to greater if higher risk groups for bleeding were targeted.
Wimmer et al 5 propose the use of alternative strategies to account for unmeasured confounding, such as falsification end points. However, it needs to be emphasized that outcome data in registries are highly dependent on the site reporting of outcomes. Only mortality was an end point we were certain was reliably collected because it is a legal requirement that all deaths in the United Kingdom are registered with the National Health Service central register, with the mortality status of every PCI performed being linked to this database. Other end points in the database were dependent on site reporting and had substantial under-reporting as was seen with the vascular complication rate, thus precluding alternative strategies to account for confounding as proposed by Wimmer et al. 5 Finally, we do not believe that our study findings diverge from other studies 4, 5 but are in fact complementary, particularly because VCDs were shown to have the greatest benefit in groups at the highest risk of bleeding. The take-home message is relatively simple-VCDs should be strongly considered for use in patients at the highest risk of bleeding if a femoral approach to PCI is to be adopted, provided there are no contraindications to their use.
